MannKind (NASDAQ:MNKD) Upgraded at HC Wainwright

HC Wainwright upgraded shares of MannKind (NASDAQ:MNKD) to a buy rating in a research report report published on Wednesday morning, MarketBeat reports. HC Wainwright currently has $9.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for MannKind’s Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at $0.05 EPS and Q4 2025 earnings at $0.05 EPS.

Several other equities analysts have also recently weighed in on the stock. Mizuho started coverage on shares of MannKind in a research note on Thursday, April 10th. They set an “outperform” rating and a $12.00 price target for the company. Wall Street Zen cut shares of MannKind from a “buy” rating to a “hold” rating in a research note on Friday, June 27th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $10.14.

MannKind Stock Performance

Shares of MNKD stock opened at $3.76 on Wednesday. The company has a market capitalization of $1.14 billion, a P/E ratio of 37.60 and a beta of 0.96. The company’s 50 day moving average price is $4.02 and its two-hundred day moving average price is $4.88. MannKind has a 52 week low of $3.51 and a 52 week high of $7.63.

MannKind (NASDAQ:MNKD) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.03 by $0.01. The firm had revenue of $78.35 million for the quarter, compared to the consensus estimate of $75.86 million. MannKind had a net margin of 10.12% and a negative return on equity of 32.41%. The business’s quarterly revenue was up 18.1% on a year-over-year basis. During the same period last year, the company posted $0.05 EPS. Analysts forecast that MannKind will post 0.1 earnings per share for the current year.

Insider Buying and Selling at MannKind

In related news, EVP David Thomson sold 32,179 shares of the firm’s stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $4.68, for a total value of $150,597.72. Following the completion of the transaction, the executive vice president directly owned 772,427 shares of the company’s stock, valued at approximately $3,614,958.36. This trade represents a 4.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Steven B. Binder sold 80,144 shares of the firm’s stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $4.69, for a total transaction of $375,875.36. Following the completion of the transaction, the director directly owned 1,006,611 shares of the company’s stock, valued at $4,721,005.59. This represents a 7.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 266,198 shares of company stock valued at $1,143,244 over the last three months. 2.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On MannKind

Several hedge funds and other institutional investors have recently made changes to their positions in MNKD. Farther Finance Advisors LLC increased its holdings in shares of MannKind by 1,379.2% in the second quarter. Farther Finance Advisors LLC now owns 7,396 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 6,896 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of MannKind in the fourth quarter valued at $37,000. Jones Financial Companies Lllp increased its holdings in shares of MannKind by 3,294.8% in the fourth quarter. Jones Financial Companies Lllp now owns 6,586 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 6,392 shares during the last quarter. Blueshift Asset Management LLC acquired a new position in shares of MannKind in the first quarter valued at $51,000. Finally, Kapitalo Investimentos Ltda acquired a new position in shares of MannKind in the second quarter valued at $51,000. 49.55% of the stock is owned by institutional investors.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.